SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.790
+0.220 (6.16%)
At close: Aug 3, 2026, 4:00 PM EDT
3.840
+0.050 (1.32%)
After-hours: Aug 3, 2026, 4:56 PM EDT
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
289.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 61.21M |
| OmniAb | 28.94M |
| Foghorn Therapeutics | 28.22M |
| Sol-Gel Technologies | 18.47M |
| Lineage Cell Therapeutics | 14.78M |
| Fate Therapeutics | 6.32M |
SABS News
- 4 days ago - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - GlobeNewsWire
- 27 days ago - Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics initiated with an Overweight at Barclays - TheFly
- 2 months ago - SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - SAB Biotherapeutics initiated with a Buy at Citi - TheFly
- 2 months ago - SAB Biotherapeutics initiated with a Buy at Jefferies - TheFly
- 2 months ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 2 months ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly